NEW YORK (GenomeWeb) – BGI has made "substantial" staff cuts at its Complete Genomics subsidiary in Mountain View, California and has put the commercialization of the Revolocity high-throughput human genome sequencing system on hold, GenomeWeb has learned.

The move is part of a change in strategy that turns Complete Genomics into an R&D organization in support of BGI's products and clinical assays, in particular its recently launched desktop sequencer, BGISEQ-500.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.

Oct
24
Sponsored by
OmniSeq

This webinar will discuss the advantages of a multiple-biomarker-based approach for immune profiling that provides clinicians with a rational means to consider approved immunotherapies or assign patients to immunotherapy clinical trials.

Nov
02
Sponsored by
Qiagen

This webinar will discuss the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Nov
09
Sponsored by
NuGEN

This webinar will discuss the role of a newly discovered, brain-enriched form of non-CpG DNA methylation in neural development and disease.

Dec
05
Sponsored by
Agilent Technologies

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.